Ad
Search
Generic filters
Filter by content type
Taxonomy terms

VCYT – Veracyte Inc

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad

Recommendation Rating

2

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 30.33

Low: 23

High: 35

Total Analysts: 9

Company Profile

Veracyte, Inc. is a genomic diagnostics company. The Company offers customized biomarker testing and analytical services. It offers a complete range of in vitro diagnostic (IVD) and companion diagnostic development services to biopharmaceutical companies and diagnostic companies. It offers tests across various diseases, which include Afirma Genomic Sequencing Classifier for thyroid cancer; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer; Prosigna Breast Cancer Assay for breast cancer; Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer; Envisia Genomic Classifier test for interstitial lung diseases; Decipher Bladder Genomic Classifier test for bladder cancer and Immunoscore Colon Cancer Test for colon cancer. It also offers Immunogram, a spatial molecular analysis and bioinformatics tool that integrates genomic, transcriptomic and proteomic data to help researchers understand the intricacies of the tumor immune microenvironment.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses